Antiplatelet therapy: Defining the optimal duration of DAPT after PCI with DES

Nature Reviews Cardiology

Volumn 12, Issue 8, 2015, Pages 445-446

  Eisen, Alon ^a   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR MORTALITY; CLINICAL DECISION MAKING; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SHORT SURVEY; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; CORONARY ARTERY DISEASE;

ASPIRIN; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84938207752     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.87     Document Type: Short Survey

References (10)

1. Bavry, A. A., & Bhatt, D. L. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet 371, 2134-2143 (2008
2. Levine, G. N., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58, e44-e122 (2011
3. Windecker, S., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35, 2541-2619 (2014
4. Bangalore, S., et al. Short-And long-Term outcomes with drug-eluting and bare-metal coronary stents: a mixed-Treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125, 2873-2891 (2012
5. Mauri, L., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 371, 2155-2166 (2014
6. Navarese, E. P., et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-Analysis of randomized controlled trials. BMJ 350, h1618 (2015
7. Palmerini, T., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-Analysis of randomised trials. Lancet http://dx.doi.org/10.1016/S0140-6736(15)60263-X
8. Palmerini, T., et al. Short-versus long-Term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-Analysis. J. Am. Coll. Cardiol. 65, 1092-1102 (2015
9. Yeh, R. W., et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2015.03.003
10. Bhatt, D. L., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006